Cell and gene therapies can be scientific miracles, but they are operational nightmares to manufacture. Unlike a small-molecule pill, an advanced therapy is often inseparable from the process that makes it, and the industry has come to depend on a specialized layer of contract development and manufacturing organizations to produce them. That CGT CDMO layer has become the critical infrastructure of the field, and in 2026 it is defined by two forces: explosive demand and a stubborn capacity bottleneck. Here is the landscape.
Why this layer exists
Most companies developing cell and gene therapies, especially the small and mid-size biotechs doing much of the pioneering work, do not own large-scale manufacturing. Building it is enormously expensive and slow, and the expertise required, in viral vectors, cell processing, and complex quality control, is scarce. So they turn to CDMOs that specialize in advanced therapies. The market has grown from a handful of players a decade ago to well over a hundred specialized providers, and it is expanding at roughly a quarter or more per year, one of the fastest-growing corners of the whole biotech economy.
The big integrated players
A set of large CDMOs offers broad capabilities across modalities and scale.
- Lonza is one of the largest and most established, with deep capabilities across cell and gene therapy manufacturing.
- Catalent, now owned by Novo Holdings following a landmark acquisition, remains a major force across advanced therapies and broader biologics.
- Thermo Fisher Scientific offers integrated manufacturing plus clinical and analytical services, appealing to sponsors who want drug substance, drug product, and testing under one roof.
- Charles River Laboratories, Samsung Biologics, Cytiva (part of Danaher), Resilience, and AGC Biologics round out the group of large, well-capitalized providers investing heavily in capacity.
- WuXi Advanced Therapies has been a leading manufacturer for approved advanced therapies, though proposed US legislation aimed at Chinese biotech providers has introduced real uncertainty for sponsors weighing long-term partnerships.
The specialists
Some of the most important providers are focused specialists, often the best choice for a specific manufacturing need.
- Aldevron is a leading independent maker of plasmid DNA and mRNA, critical raw materials that sit upstream of almost every viral-vector and mRNA process, meaning it supplies inputs to much of the rest of the industry.
- Oxford Biomedica is a specialist in viral vectors, particularly lentiviral vectors used in many cell and gene therapies.
- FUJIFILM, through its cell-therapy and biologics businesses, brings deep capability in areas including induced pluripotent stem cell technologies.
- Forge Biologics (now part of Ajinomoto) focuses on AAV gene-therapy manufacturing, and a growing roster of specialists, from viral-vector houses to emerging regional players, serve specific niches.
The viral-vector bottleneck
The single biggest constraint in the field is capacity for viral vectors, the engineered viruses (chiefly AAV and lentivirus) that deliver genetic material in most gene therapies. Producing them is technically difficult, requires specialized facilities, and suffers from long lead times and batch-to-batch variability, and there simply is not enough qualified capacity to meet demand. This shortage is a genuine drag on the whole field, and it is why so much CDMO investment is flowing into vector production. For a sponsor, securing vector capacity early, well before you need it, is one of the most important operational moves you can make.
The consolidation wave
The other defining feature of the moment is dealmaking. The CGT manufacturing space has seen a steady stream of mergers and acquisitions as larger players buy capacity and specialists, from the acquisition of Catalent by Novo Holdings to the purchase of specialist vector and cell-therapy manufacturers by larger strategics. Consolidation brings scale and integration, but it also reshuffles the landscape quickly, so the roster of who owns whom is worth checking before you commit to a multi-year manufacturing relationship.
What to look for in a CGT CDMO
Choosing among these partners comes down to fit, not brand. The factors that matter most are modality match, viral-vector expertise, cell-processing capability, or plasmid and mRNA production, depending on exactly what you need; a clean regulatory and inspection track record, since a CDMO’s compliance history becomes your risk; genuinely available capacity on a timeline that matches yours, not a promise of capacity that materializes late; and, increasingly, supply-chain considerations, including where a provider is based, given the shifting policy environment. As always, the cost of a failed batch or a delayed launch dwarfs any savings from picking the cheapest option.
Go deeper on the specific players
The supply-chain question and the make-or-buy decision
Two forces increasingly shape CGT manufacturing strategy beyond the choice of provider. The first is policy and supply-chain risk. Proposed US legislation aimed at certain Chinese biotech service providers has injected real uncertainty into partnerships that once looked purely operational, prompting many sponsors to think harder about where their manufacturing partners are based and how resilient their supply chains are. In a field already constrained by scarce capacity, adding geopolitical considerations makes early, careful planning even more important, and it has accelerated interest in diversified and regionally distributed manufacturing.
The second is the perennial make-or-buy question. A handful of larger or better-funded developers choose to build their own manufacturing, reasoning that for a complex advanced therapy, owning the process, and the deep know-how that comes with it, is a strategic advantage worth the enormous cost and time. Most emerging companies, however, rely on CDMOs, because building capacity is prohibitively expensive and slow and because the specialized expertise is hard to assemble in-house. The right answer depends on a company’s scale, capital, and how central manufacturing is to its competitive edge, but for the great majority, partnering with a capable CDMO, and securing capacity early given the bottlenecks, is the only realistic path to the clinic and the market. Whichever route a company takes, the manufacturing decision is not a late-stage detail; in advanced therapies it is a core strategic choice that should be made early and revisited as the program grows.
Why this market matters so much
It is worth stepping back to see the scale of what is happening here. The cell and gene therapy manufacturing market is measured in the billions of dollars and growing at roughly a quarter or more per year, one of the fastest expansions anywhere in life science, driven by a swelling pipeline of advanced therapies moving through the clinic. Every one of those programs needs manufacturing, and because so few developers own their own capacity, that demand flows to the CDMO layer. This is why the manufacturing bottleneck is not a niche operational detail but a genuine determinant of how quickly the whole field can bring cures to patients: the therapies that reach the market in the years ahead will, in part, be decided by which ones could actually be made. For investors, the manufacturing layer offers a picks-and-shovels way to back the growth of advanced therapies without betting on any single treatment. For developers, it is the infrastructure their entire timeline depends on. Either way, the CDMOs profiled here sit at the strategic heart of one of medicine’s most important frontiers.
The one move that matters most
If there is a single piece of practical advice for any company developing an advanced therapy, it is this: secure your manufacturing capacity early, earlier than feels necessary. In a field where qualified capacity, especially for viral vectors, is genuinely scarce, the companies that get burned are the ones that treat manufacturing as a later-stage problem and then find there is no slot available when they need to make clinical or commercial material. Engaging a capable CDMO well ahead of need, and building the relationship before the pressure is on, is one of the highest-leverage decisions in the whole development timeline. In advanced therapies, manufacturing is not a downstream detail; it is often the gating factor that determines whether a program reaches patients on schedule.
This is a fast-moving landscape, and the specific roster shifts with every capacity expansion and acquisition. For a regularly updated, detailed guide to the CDMOs manufacturing advanced therapies, browse the BioMed Nexus CDMO directory, and to stay current on the capacity expansions, partnerships, and deals reshaping cell and gene therapy manufacturing, the daily brief tracks the sector as it evolves.
Frequently asked questions
Who are the leading cell and gene therapy CDMOs?
Large integrated providers include Lonza, Catalent (owned by Novo Holdings), Thermo Fisher, Charles River, Samsung Biologics, Cytiva, Resilience and AGC Biologics. Important specialists include Aldevron (plasmid DNA and mRNA), Oxford Biomedica (viral vectors), FUJIFILM and Forge Biologics (AAV). The roster shifts frequently with consolidation.
Why is there a viral vector shortage?
Viral vectors, the engineered viruses that deliver genetic material in most gene therapies, are technically difficult to produce, require specialized facilities, and suffer long lead times and batch-to-batch variability. There is not enough qualified manufacturing capacity to meet surging demand, which makes securing vector capacity early a critical operational priority for sponsors.
How do I choose a cell and gene therapy CDMO?
Match the CDMO to your exact modality, whether you need viral-vector, cell-processing, or plasmid and mRNA capability, and evaluate its regulatory and inspection track record, genuinely available capacity on your timeline, and supply-chain factors including geography given the shifting policy environment. Fit and track record matter more than brand or price.
